Shree Ganesh Remedies Ltd
Shree Ganesh Remedies is engaged in the business of Pharma Intermediate.
- Market Cap ₹ 782 Cr.
- Current Price ₹ 610
- High / Low ₹ 736 / 282
- Stock P/E 80.2
- Book Value ₹ 41.9
- Dividend Yield 0.08 %
- ROCE 27.8 %
- ROE 23.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 14.6 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| 35.22 | 64.01 | 49.08 | |
| 26.49 | 51.50 | 35.43 | |
| Operating Profit | 8.73 | 12.51 | 13.65 |
| OPM % | 24.79% | 19.54% | 27.81% |
| 1.17 | 3.91 | 2.09 | |
| Interest | 0.20 | 0.54 | 0.07 |
| Depreciation | 1.04 | 2.29 | 2.73 |
| Profit before tax | 8.66 | 13.59 | 12.94 |
| Tax % | 28.06% | 22.96% | 24.65% |
| 6.24 | 10.47 | 9.75 | |
| EPS in Rs | 4.88 | 8.18 | 7.62 |
| Dividend Payout % | 17.97% | 12.85% | 17.97% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 36% |
| 1 Year: | 95% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Sep 2021 | |
|---|---|---|---|
| Equity Capital | 8.97 | 8.97 | 10.01 |
| Reserves | 24.85 | 33.23 | 43.58 |
| 0.75 | 4.47 | 1.12 | |
| 6.77 | 8.61 | 9.97 | |
| Total Liabilities | 41.34 | 55.28 | 64.68 |
| 14.50 | 20.14 | 26.02 | |
| CWIP | 0.00 | 0.00 | 0.86 |
| Investments | 4.05 | 3.07 | 0.07 |
| 22.79 | 32.07 | 37.73 | |
| Total Assets | 41.34 | 55.28 | 64.68 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| -5.22 | 4.59 | 3.31 | |
| -0.08 | -2.91 | -0.94 | |
| -0.18 | -0.48 | -0.66 | |
| Net Cash Flow | -5.47 | 1.20 | 1.71 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Debtor Days | 100.73 | 101.44 | |
| Inventory Days | 125.46 | 60.91 | |
| Days Payable | 75.16 | 42.95 | |
| Cash Conversion Cycle | 151.03 | 119.40 | |
| Working Capital Days | 148.72 | 115.07 | |
| ROCE % | 34.77% |
Documents
Announcements
- Commencement Of Trial Run. 17 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Apr
- Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015 For Year Ended On March 31, 2024. 5 Apr
- Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (LODR) Regulations, 2015 For The Year Ended On March 31, 2024 5 Apr
- Closure of Trading Window 26 Mar
Business segments[1]
Pharmaceutical intermediates: 32+ products; 54 Cr sales in FY23 (vs 51 Cr in FY22)
Human pharma segments: Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic
Veterinary segment: Feed Additives, Antiparasitic, Anti-Inflammator
Fine and Specialty Chemicals: 11+ products; 37 Cr. sales in FY23 (vs 20 Cr. in FY22)
Industries served: Aroma & Health, Agrochem, Polymer, Electronics